MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients-Reference-Cited by-同舟云学术

MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients

Published:2019-11-06 Issue:4 Volume:33 Page:531-540
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Chang Hsiu-Hao,Tseng Yu-Fen,Lu Meng-Yao,Yang Yung-Li,Chou Shu-Wei,Lin Dong-Tsamn,Lin Kai-Hsin,Jou Shiann-Tarng,Hsu Wen-Ming,Jeng Yung-Ming

Funder

National Taiwan University Hospital

Ministry of Science and Technology, Taiwan

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/s41379-019-0410-x.pdf

Reference36 articles.

1. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411.

2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20.

3. Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer. 1997;80:2321–32.

4. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–34.

5. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008–17.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma;Pediatric Blood & Cancer;2024-07-05

2. MYCN in human development and diseases;Frontiers in Oncology;2024-05-31

3. CKLF instigates a “cold” microenvironment to promote MYCN-mediated tumor aggressiveness;Science Advances;2024-03-15

4. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene orMYCNgene;Journal of Clinical Pathology;2023-05-23

5. Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma;Journal for ImmunoTherapy of Cancer;2023-05